Altered efficacy of AT1R-targeted treatment after spontaneous cancer cell-AT1R upregulation

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Ager, Eleanor I ^a   Wen, Shu W ^a   Chan, Joyna ^a   Chong, Way W ^a   Neo, Jaclyn H ^a   Christophi, Christopher ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Biomarker; Combination therapy; Liver metastases; Renin angiotensin system

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN[1-7]; CAPTOPRIL; CASPASE 3; CD34 ANTIGEN; IRBESARTAN; KI 67 ANTIGEN; NICOTINOYLTYROSYL(N BENZYLOXYCARBONYLARGINYL)LYSYLHISTIDYLPROLYLISOLEUCINE; VASCULOTROPIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN I; ANGIOTENSIN I (1 7); ANGIOTENSIN I (1-7); BIPHENYL DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; OLIGOPEPTIDE; PEPTIDE FRAGMENT; TETRAZOLE DERIVATIVE; TUMOR MARKER; TUMOR PROTEIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; CANCER INFILTRATION; CANCER INHIBITION; CANCER SIZE; CELL PROLIFERATION; CELL SPECIFICITY; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LIVER WEIGHT; MALE; MOUSE; NONHUMAN; PATIENT SELECTION; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VASCULARIZATION; ADENOCARCINOMA; ANIMAL; BIOSYNTHESIS; CBA MOUSE; COLORECTAL TUMOR; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; METABOLISM; METASTASIS; MOLECULARLY TARGETED THERAPY; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; TUMOR VOLUME; UPREGULATION;

ADENOCARCINOMA; ANGIOTENSIN I; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BIPHENYL COMPOUNDS; CAPTOPRIL; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED CBA; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79959436463     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-274     Document Type: Article

References (33)

1. McLoughlin JM, Jensen EH, Malafa M. Resection of colorectal liver metastases: current perspectives. Cancer Control 2006, 13(1):32-41.
2. Neo JH, Ager EI, Angus PW, Zhu J, Herath CB, Christophi C. Changes in the renin angiotensin system during the development of colorectal cancer liver metastases. BMC cancer 2010, 10:134. 10.1186/1471-2407-10-134, 2860361, 20380732.
3. Neo JH, Malcontenti-Wilson C, Muralidharan V, Christophi C. Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases. J Gastroenterol Hepatol 2007, 22(4):577-584. 10.1111/j.1440-1746.2006.04797.x, 17376054.
4. Hunyady L, Catt KJ. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Molecular endocrinology (Baltimore, Md 2006, 20(5):953-970.
5. Ager EI, Chong WW, Wen SW, Christophi C. Targeting the antiogensin II type 2 receptor (AT2R) in colorectal liver metastases. Cancer cell international 2010, 10(1):19. 10.1186/1475-2867-10-19, 2902462, 20584290.
6. Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger T. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. The Journal of clinical investigation 1995, 95(2):651-657. 10.1172/JCI117710, 295531, 7860748.
7. Santos RA, Ferreira AJ. Angiotensin-(1-7) and the renin-angiotensin system. Current opinion in nephrology and hypertension 2007, 16(2):122-128. 10.1097/MNH.0b013e328031f362, 17293687.
8. Gallagher PE, Tallant EA. Inhibition of human lung cancer cell growth by angiotensin-(1-7). Carcinogenesis 2004, 25(11):2045-2052. 10.1093/carcin/bgh236, 15284177.
9. Menon J, Soto-Pantoja DR, Callahan MF, Cline JM, Ferrario CM, Tallant EA, Gallagher PE. Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2. Cancer research 2007, 67(6):2809-2815. 10.1158/0008-5472.CAN-06-3614, 17363603.
10. Petty WJ, Miller AA, McCoy TP, Gallagher PE, Tallant EA, Torti FM. Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone. Clin Cancer Res 2009, 15(23):7398-7404. 10.1158/1078-0432.CCR-09-1957, 19920106.
11. Uemura H, Hoshino K, Miyoshi Y, Kubota Y, Noguchi K, Takahashi S. Clinical trial and basic investigation: Angiotensin II receptor blocker decelerates PSA failure after radical retropubic prostatectomy. Journal of Clinical Oncology 2008, 26(15S):14676.
12. Kuruppu D, Christophi C, Bertram JF, O'Brien PE. Characterization of an animal model of hepatic metastasis. J Gastroenterol Hepatol 1996, 11(1):26-32. 10.1111/j.1440-1746.1996.tb00006.x, 8672738.
13. Leenen FH, Yuan B. Prevention of hypertension by irbesartan in Dahl S rats relates to central angiotensin II type 1 receptor blockade. Hypertension 2001, 37(3):981-984.
14. Zhang Y, Griendling KK, Dikalova A, Owens GK, Taylor WR. Vascular hypertrophy in angiotensin II-induced hypertension is mediated by vascular smooth muscle cell-derived H2O2. Hypertension 2005, 46(4):732-737. 10.1161/01.HYP.0000182660.74266.6d, 16172434.
15. Hirano T, Ran J, Adachi M. Opposing actions of angiotensin II type 1 and 2 receptors on plasma cholesterol levels in rats. Journal of hypertension 2006, 24(1):103-108. 10.1097/01.hjh.0000198030.30095.98, 16331107.
16. Funao K, Matsuyama M, Kawahito Y, Sano H, Chargui J, Touraine JL, Nakatani T, Yoshimura R. Telmisartan is a potent target for prevention and treatment in human prostate cancer. Oncology reports 2008, 20(2):295-300.
17. Fujita M, Hayashi I, Yamashina S, Itoman M, Majima M. Blockade of angiotensin AT1a receptor signaling reduces tumour growth, angiogenesis, and metastasis. Biochemical and biophysical research communications 2002, 294(2):441-447. 10.1016/S0006-291X(02)00496-5, 12051731.
18. Suganuma T, Ino K, Shibata K, Kajiyama H, Nagasaka T, Mizutani S, Kikkawa F. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumour invasion, angiogenesis, and peritoneal dissemination. Clin Cancer Res 2005, 11(7):2686-2694. 10.1158/1078-0432.CCR-04-1946, 15814650.
19. Kosaka T, Miyajima A, Takayama E, Kikuchi E, Nakashima J, Ohigashi T, Asano T, Sakamoto M, Okita H, Murai M, Hayakawa M. Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer. Prostate 2007, 67(1):41-49. 10.1002/pros.20486, 17044086.
20. Isobe A, Takeda T, Sakata M, Miyake A, Yamamoto T, Minekawa R, Nishimoto F, Oskamoto Y, Walker CL, Kimura T. Dual repressive effect of angiotensin II-type 1 receptor blocker telmisartan on angiotensin II-induced and estradiol-induced uterine leiomyoma cell proliferation. Human reproduction (Oxford, England) 2008, 23(2):440-446.
21. Ishiguro H, Ishiguro Y, Kubota Y, Uemura H. Regulation of prostate cancer cell growth and PSA expression by angiotensin II receptor blocker with peroxisome proliferator-activated receptor gamma ligand like action. Prostate 2007, 67(9):924-932. 10.1002/pros.20571, 17440964.
22. Leung PS, Suen PM, Ip SP, Yip CK, Chen G, Lai PB. Expression and localization of AT1 receptors in hepatic Kupffer cells: its potential role in regulating a fibrogenic response. Regul Pept 2003, 116(1-3):61-69. 10.1016/S0167-0115(03)00192-7, 14599716.
23. Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory micro-environment in tumour progression: The role of tumour-associated macrophages. Crit Rev Oncol Hematol 2007,
24. Ager EI, Neo J, Christophi C. The renin-angiotensin system and malignancy. Carcinogenesis 2008, 29(9):1675-1684. 10.1093/carcin/bgn171, 18632755.
25. Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer?. Trends Endocrinol Metab 2005, 16(7):293-299. 10.1016/j.tem.2005.07.009, 16061390.
26. Fujiyama S, Matsubara H, Nozawa Y, Maruyama K, Mori Y, Tsutsumi Y, Masaki H, Uchiyama Y, Koyama Y, Nose A, Iba O, Tateishi E, Ogata N, Jyo N, Higashiyama S, Iwasaka T. Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation. Circulation research 2001, 88(1):22-29.
27. Silvestre JS, Tamarat R, Senbonmatsu T, Icchiki T, Ebrahimian T, Iglarz M, Besnard S, Duriez M, Inagami T, Levy BI. Antiangiogenic effect of angiotensin II type 2 receptor in ischemia-induced angiogenesis in mice hindlimb. Circulation research 2002, 90(10):1072-1079. 10.1161/01.RES.0000019892.41157.24, 12039796.
28. Clere N, Corre I, Faure S, Guihot AL, Vessieres E, Chalopin M, Morel A, Coqueret O, Hein L, Delneste Y, Paris F, Henrion D. Deficiency or blockade of angiotensin II type 2 receptor delays tumourigenesis by inhibiting malignant cell proliferation and angiogenesis. International journal of cancer 2010, 127(1):2279-2291.
29. Pawlikowski M. Immunohistochemical detection of angiotensin receptors AT1 and AT2 in normal rat pituitary gland, estrogen-induced rat pituitary tumour and human pituitary adenomas. Folia histochemica et cytobiologica / Polish Academy of Sciences, Polish Histochemical and Cytochemical Society 2006, 44(3):173-177.
30. Ptasinska-Wnuk D, Lawnicka H, Fryczak J, Kunert-Radek J, Pawlikowski M. Angiotensin peptides regulate angiogenic activity in rat anterior pituitary tumour cell cultures. Endokrynologia Polska 2007, 58(6):478-486.
31. Yoshiji H, Kuriyama S, Fukui H. Perindopril: possible use in cancer therapy. Anti-cancer drugs 2002, 13(3):221-228. 10.1097/00001813-200203000-00003, 11984065.
32. Wang L, Cai SR, Zhang CH, He YL, Zhan WH, Wu H, Peng JJ. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on lymphangiogenesis of gastric cancer in a nude mouse model. Chinese medical journal 2008, 121(21):2167-2171.
33. Nakagawa T, Kubota T, Kabuto M, Kodera T. Captopril inhibits glioma cell invasion in vitro: involvement of matrix metalloproteinases. Anticancer research 1995, 15(5B):1985-1989.